Condensed Consolidated Financial Statement Details (Tables)

3 Months Ended

Mar. 31, 2024

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory consists of the following (in thousands):

	March 31, 2024		December 31, 2023
Raw materials	$	1,936	$	1,861
Work-in-process		9,962		12,880
Finished goods		4,340		1,360
Total inventory, net	$	16,238	$	16,101

Schedule of Other Current Assets

Other current assets consist of the following (in thousands):

	March 31, 2024		December 31, 2023
Prepaid research and development expenses	$	4,767	$	4,325
Non-trade receivables and other		1,816		1,047
Other prepaid expenses		4,160		4,407
Total other current assets	$	10,743	$	9,779

Schedule of Accrued Expenses

Accrued expenses consist of the following (in thousands):

	March 31, 2024		December 31, 2023
Accrued compensation	$	7,384	$	5,553
Accrued clinical trial expenses		4,233		4,321
Liability to collaboration partners		1,310		2,678
Accrued contract termination costs		3,043		3,020
Other accrued expenses		8,311		6,590
Total accrued expenses	$	24,281	$	22,162

Schedule of Liability Related to Sale of Potential Future Royalties

The following is a reconciliation of the changes in our liabilities related to the sales of future royalties for the three months ended March 31, 2024 (in thousands):

	Three Months Ended March 31, 2024
	2012 Purchase and Sale Agreement			2020 Purchase and Sale Agreement			Total
Liabilities related to the sales of future royalties, net – beginning balance	$	24,217		$	88,408		$	112,625
Non-cash royalty revenue		(6,944	)		(8,564	)		(15,508	)
Non-cash interest expense		1,831			3,700			5,531
Amortization of transaction costs		—			209			209
Proceeds from the Amendment		—			15,000			15,000
Liabilities related to the sales of future royalties, net – ending balance	$	19,104		$	98,753		$	117,857